End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 EUR | -20.00% | -20.00% | -66.67% |
2023 | Vitruvia Medical AG Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2022 | Vitruvia Medical AG announced that it expects to receive CHF 2.2 million in funding | CI |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 28.32 | 4.071 |
Enterprise Value (EV) 1 | 28.27 | 4.914 |
P/E ratio | - | -2.62 x |
Yield | - | - |
Capitalization / Revenue | 14.4 x | 2.67 x |
EV / Revenue | 14.4 x | 3.22 x |
EV / EBITDA | -36.4 x | -5.39 x |
EV / FCF | - | - |
FCF Yield | - | - |
Price to Book | - | -2.44 x |
Nbr of stocks (in thousands) | 1,770 | 1,770 |
Reference price 2 | 16.00 | 2.300 |
Announcement Date | 6/25/23 | 6/25/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net sales 1 | 5.772 | 1.966 | 1.526 |
EBITDA 1 | -0.9605 | -0.7757 | -0.9121 |
EBIT 1 | -1.313 | -1.128 | -1.344 |
Operating Margin | -22.74% | -57.36% | -88.12% |
Earnings before Tax (EBT) 1 | -1.496 | -8.133 | -1.467 |
Net income 1 | -1.545 | -8.132 | -1.485 |
Net margin | -26.76% | -413.55% | -97.31% |
EPS 2 | -1.046 | - | -0.8774 |
Free Cash Flow | - | - | - |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 5/3/21 | 6/25/23 | 6/25/23 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net Debt 1 | - | - | 0.84 |
Net Cash position 1 | 0.71 | 0.05 | - |
Leverage (Debt/EBITDA) | - | - | -0.9244 x |
Free Cash Flow | - | - | - |
ROE (net income / shareholders' equity) | - | -435% | 170% |
ROA (Net income/ Total Assets) | - | -13.8% | -39.5% |
Assets 1 | - | 58.87 | 3.762 |
Book Value Per Share 2 | 2.630 | - | -0.9400 |
Cash Flow per Share 2 | 0.4800 | - | 0.1300 |
Capex 1 | 2.91 | - | - |
Capex / Sales | 50.44% | - | - |
Announcement Date | 5/3/21 | 6/25/23 | 6/25/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-66.67% | 989K | |
+4.63% | 32.55B | |
+18.46% | 7.66B | |
+20.94% | 3.85B | |
-17.01% | 3.14B | |
-22.16% | 1.35B | |
-31.01% | 1.18B | |
+4.40% | 934M | |
-34.81% | 911M | |
-25.64% | 840M |
- Stock Market
- Equities
- 991 Stock
- Financials Vitruvia Medical AG